DYRK1A and Dravet syndrome: If EGCG or any other drug targeting trisomic DYRK1A is to be considered as a rational treatment for DS phenotypes, it is important that treatment efficacy be contingent on and optimized for inhibition of DYRK1A in brain (or other) tissues implicated in the deficits observed in DS.